Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 29, 2006

View Archived Issues

Snapshots of newly reported clinical trials in leukemia, myelodysplastic syndromes: II

Encouraging clinical, preclinical data on siplizumab presented

Beta-lactamase inhibitor NXL-104 enters phase I

Imvamune equally immunogenic in HIV-infected subjects as healthy subjects

Positive data for Nastech's PYY(3-36) nasal spray

MK-0457 begins pivotal phase II study in treatment-resistant advanced leukemias

Introgen obtains license to patent applications covering INGN-241 uses

Recordati and sigma-tau to comarket new antihypertensive drug in Italy

New phase II trial investigates SNS-595 in ovarian cancer

Positive preliminary data for Oxycyte in traumatic brain injury

Data finalized from phase II study of talabostat plus docetaxel in NSCLC

NIAID to study Emergent's group B streptococcus vaccine candidate

YM partners with TTY in Taiwan for tesmilifene in hepatic cancer

Labopharm files complete response to once-daily tramadol approvable letter

Topline phase I findings for AZ-003

Encouraging findings for CTCE-0214 in healthy volunteers

Intranasal PH-80 provides significant improvements in PMS symptoms

Volinanserin enhances the antidepressant effects of desipramine and tranylcypromine in rats

Otsuka granted Japanese rights to saxagliptin

Faropenem phase III trial stopped to consider exclusion of Ketek arm

New phase II trial studies XL-880 in patients with gastric cancer

Valeant sells HIV and cancer programs to Ardea

Cimzia shows positive effect on ACR scores in rheumatoid arthritis

Preliminary findings from three Telcyta phase III studies

Clinical efficacy and safety of bifeprunox reported in patients with acute and stable schizophrenia

Novel agents for transplant rejection revealed in recent patents

Compounds for possible use in anxiety, depression, etc., claimed in recent patents

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...